Sequestration of nerve growth factor (NGF) significantly attenuates skeletal pain in both animals and humans. However, relatively little is known about the specific cell types that express NGF or its cognate receptors tropomyosin receptor kinase A (TrkA) and p75 in the intact bone and articular cartilage. In the present study, antibodies raised against NGF, TrkA, and p75 (also known as CD271) were used to explore the expression of these antigens in the non-decalcified young mouse femur. In general, all three antigens displayed a remarkably restricted expression in bone and cartilage with less than 2% of all DAPIþ cells in the femur displaying expression of any one of the three antigens. Robust NGF immunoreactivity was found in mostly CD-31À blood vessel-associated cells, a small subset of CD-31þ endothelial cells, an unidentified group of cells located at the subchondral bone/articular cartilage interface, and a few isolated, single cells in the bone marrow. In contrast, p75 and TrkA were almost exclusively expressed by nerve fibers located nearby NGFþ blood vessels. The only non-neuronal expression of either p75 or TrkA in the femur was the expression of p75 by a subset of cells located in the deep and middle zone of the articular cartilage. Understanding the factors that tightly regulate the basal level of expression in normal bone and how the expression of NGF, TrkA, and p75 change in injury, disease, and aging may provide insights into novel therapies that can reduce skeletal pain and improve skeletal health.
Introduction
There continues to be a significant unmet need for safe and effective medications that attenuate skeletal pain. [1] [2] [3] [4] [5] Opioids and nonsteroidal anti-inflammatory drugs (NSAIDs) still dominate the clinical landscape as they are the most frequently used therapies to relieve chronic skeletal pain despite their limited effectiveness and considerable side-effect profile. 6, 7 Thus, although there has been a myriad of pain targets proposed over the past several decades, the majority of these pharmacotherapies for treating skeletal pain have failed to come to market. [8] [9] [10] In the last decade, nerve growth factor (NGF) and its interaction with its cognate receptor tropomyosin receptor kinase A (TrkA) have come to be recognized as important mediators of skeletal pain. [11] [12] [13] Pharmacotherapies targeting this pathway are now considered promising targets for the treatment of a variety of skeletal pain conditions including osteoarthritis (OA), 13-15, low back pain, [16] [17] [18] [19] bone fracture, 20, 21 orthopedic surgery, 22 and bone cancer. 23, 24 Several methodologic approaches, including sequestration of free NGF, 12 prevention of NGF binding and TrkA activation, 25 and inhibition of TrkA function, [26] [27] [28] have been investigated in the development of new pharmacotherapies. Among these, NGF-sequestering antibodies have exhibited significant clinical promise and results from these clinical trials have been extensively published in peer-reviewed journals.
However, in 2010, a small subset of OA patients who were receiving anti-NGF exhibited rapid joint destruction leading to earlier than expected joint replacement. This prompted the US Food and Drug Administration (FDA) to place a hold on all clinical trials involving anti-NGF antibodies. Although this hold was lifted in 2015, and clinical trials for anti-NGF are again moving forward, in 2012 the FDA commissioned an independent arthritis advisory committee to further investigate these claims and concluded that joint failures were probably related to anti-NGF treatment and represented a unique clinical form of rapidly progressive OA, citing rapid and considerable joint destruction typically within 6-12 months of exposure. 29 These cases were characterized by pathological features including femoral head flattening and medial femoral condyle involvement with subchondral fractures, associated edema, joint effusions, and marked pain. The committee also determined that events were more likely to occur with higher doses, longer exposures, and concurrent NSAID use. Although the precise etiology is still not known, several plausible mechanisms were discussed including higher susceptibility in patients with atrophic and neuropathic forms of OA, subchondral bone pathology, possible drug toxicity with concurrent NSAID use, and simply excessive overuse of the now less painful arthritic joints. 29 Given the evidence that NGF plays an important role in driving skeletal pain, one important data set that we still do not have is what specific cells in the in vivo bone express NGF, TrkA, or p75. 4, [30] [31] [32] In large part, this lack of knowledge may be because, for many antibodies, the decalcification process will denature the epitope recognized by the antibody making it difficult or impossible to detect any specific immunohistochemical staining. In the present report, this issue is addressed by also examining the young mouse femur which is both small and relatively non-calcified so that decalcification was not required, thus potentially preserving the antigenicity of NGF, TrkA, and p75 in a large load bearing bone.
Materials and methods Animals
Experiments were performed on 20 young (10 days old), 10 adult (4 months old), and 10 aging (24 months old) male C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME). Since the present study was only examining normal mice, both femurs were obtained from each mouse providing 40 young, 20 adult, and 20 aging femurs that were used in the present study. The mice were housed in accordance with the National Institutes of Health guidelines under specific pathogen-free conditions in autoclaved cages maintained at 22 C with a 12-h alternating light/dark cycle and access to food and water ad libitum. All procedures adhered to the guidelines of the Committee for Research and Ethical Issues of the International Association for the Study of Pain and were approved by the Institutional Animal Care and Use Committee at the University of Arizona (Tucson, AZ, USA) (Protocol Number: 08-005).
Preparation of tissue for immunohistochemistry and histology
Young mice (10 days old) were deeply anesthetized with CO 2 delivered from a compressed gas cylinder then decapitated. Young hindlimbs were then excised and placed in 4% formaldehyde/12.5% picric acid solution in 0.1 M phosphate-buffered saline (PBS) (pH 6.9 at 4 C) overnight. Following fixation, the femurs were dissected out and either placed in PBS (pH 7.4) for 48 h and then cryoprotected in 30% sucrose at 4 C for 2 weeks or the femurs were placed in a decalcification solution for 2 weeks (0.5 M ethylene-diamine-tetra-acetic acid (EDTA) in PBS, pH 7.4 at 4 C) and then cyroprotected in 30% sucrose at 4 C for at least 48 h before sectioning. Thus, half of the young femurs (20 femurs) were placed in the same decalcification solution used to demineralize adult and aging femurs before tissue sectioning, while the other 20 young femurs were sectioned without going through the decalcification process.
The adult and aging mice were deeply anesthetized with ketamine/xylazine (0.01 ml/g, 100 mg/10 kg, s.c.) and perfused intracardially as described previously. [33] [34] [35] Briefly, mice were perfused intracardially with a fixative solution of 4% formaldehyde/12.5% picric acid solution in 0.1 M PBS (pH 6.9 at 4 C). Following perfusion, hindlimbs were removed and postfixed in the same fixative solution overnight. Following fixation, the femurs were decalcified for two weeks in 0.5 M EDTA in PBS, pH 7.4 at 4 C. For all femurs that went through the decalcification protocol, the EDTA solution was changed daily. In the adult and aging mice, decalcification was monitored weekly radiographically with a Faxitron MX-20 digital cabinet X-ray system (Faxitron/Bioptics, Tucson, AZ, USA). Following the two-week decalcification procedure, each femur was cryoprotected in 30% sucrose at 4 C for at least 48 h before being sectioned. Serial tissue sections of young, adult, and aging femurs were cut at thickness of either 20 or 60 mm and thaw mounted with two sections of bone per gelatincoated slide. Sections at 20 mm thickness were stained with Safranin O or hematoxylin and eosin (H&E), and the 60 -mm-thick sections were used for immunohistochemistry and confocal microscopy.
Immunohistochemistry and histology
To process the tissue for immunohistochemistry or histology, sectioned slides were dried at room temperature (RT) for 30 min and then washed in PBS for 3 Â 10 min. For slides used in histology, following this PBS wash the slides were stained with Safranin O or H&E. For slides to be used for immunohistochemistry, the slides were blocked with 3% normal donkey serum (Jackson ImmunoResearch, Cat# 017-11-121; West Grove, PA, USA) in PBS with 0.3% Triton-X 100 (Sigma Chemical Co., Cat# X100; St. Louis, MO, USA) for 1 h. Afterwards, the slides were incubated overnight with primary antibodies made in 1% normal donkey serum and 0.1% Triton-X 100 in 0.1 M PBS at RT. NGF was labeled using an antibody from Santa Cruz (Dallas, TX, USA; polyclonal rabbit anti-mouse, 1:1000, Cat# SC-548). TrkA was labeled with a polyclonal goat anti-mouse (1:1000, Cat# AF1056; R&D Systems, Minneapolis, MN, USA) and p75 was labeled with a polyclonal rabbit anti-mouse (1:1000, Cat# AB1554; Millipore, Temecula, CA, USA). Peptide-rich sensory nerve fibers were labeled with an antibody against calcitonin gene-related peptide (CGRP; polyclonal rabbit anti-rat CGRP; 1:10,000; Cat #8198; Sigma Chemical Co.). Sympathetic nerve fibers were identified using an antibody against tyrosine hydroxylase (TH; polyclonal rabbit anti-mouse TH, 1:1000, Cat #AB152; Millipore). Endothelial cells were identified using an antibody raised against cluster differentiation-31, PECAM-1 (polyclonal rabbit anti-mouse CD31; 1:500, Cat #550274; BD Pharmingen, San Jose, CA, USA).
After primary antibody incubation, preparations were washed 3 Â 10 min each in PBS and incubated for 3 h at RT with secondary antibodies conjugated to fluorescent markers (Cy3/Dylight 488/AlexaFluor; 1:600 and 1:400; Jackson ImmunoResearch). Preparations were then washed 3 Â 10 min each in PBS. Cellular nuclei were labeled using 4 0 ,6-diamidino-2-phenylindole (DAPI) (1:500; Cat#D21490; Invitrogen, Grand Island, NY, USA) followed by an additional 3 Â 10 min wash in PBS. Slides were dehydrated through an alcohol gradient (2 min each; 70%, 80%, 90%, and 100%), cleared in xylene (2 Â 2 min), and cover slipped with di-nbutylphthalate-polystyrene-xylene (Sigma Chemical Co., Cat#06522). Preparations were allowed to dry covered at RT for 12 h before imaging.
Bright field and laser confocal microscopy
Bright field images of histologically stained sections were acquired using an Olympus BX51 microscope fitted with an Olympus DP70 digital CCD. Confocal images of NGF, TrkA, p75 CGRP, TH, and CD31 were acquired using an Olympus FV1200 microscope (Olympus Life Sciences, Center Valley, PA) and a 60 Â /1.42 PlanApo N objective using excitation beams of 488 and 599 nm, and emissions were detected using BA505-540 and B575-620 emission filters. Nuclear staining (DAPI) was visualized using an excitation beam of 405 nm and emissions were detected using a BA430-470 emission filter. Sequential acquisition mode was used to reduce bleedthrough from fluorophores. The average volume of data that was collected was 211.7 mm Â 211.7 mm Â 60 mm, with each Z-axis slice being 1.0 mm/slice.
Assessment of immunohistochemical staining
To assess the effect of the decalcification process on immunohistochemical staining, we examined CGRP, TH, CD31, NGF, TrkA, and p75 staining in tissue sections obtained from non-decalcified young bone and decalcified young, adult, and aging bone. For every antibody we examined, tissues from the non-decalcified young femur and the decalcified young, adult, and aging femur were examined from at least six different animals. Sections were examined under an Olympus FV1200 confocal microscope using a 60 Â objective, under which it was easily possible to obtain single cell resolution and to distinguish individual nerve fibers. The distal end of the femur was selected for evaluation, as this area of bone allows easy anatomical orientation and has significant articular cartilage in the femoral knee joint, a thick periosteum, and abundant and well vascularized bone marrow. To qualitatively assess the effect that the decalcification process had on young bones, and the quality of staining we were able to obtain in young, adult, and aging bones, a scale of À to þþþ was used. The À indicates no detectable signal; (þ) indicates signal at the very limit of detection, þ indicates minimal detection, requires significant increase in laser power to visualize; þþ indicates average staining signal, requires minimal increase in laser power to visualize; þþþ indicates maximum staining signal, requires no increase in laser power to visualize.
Results
The expression of NGF in bone and articular cartilage of the young femur For every antibody used in this study (NGF, TrkA, p75, CGRP, TH, and CD-31), we examined tissues from the non-decalcified young femur and the decalcified young, adult, and aging femur in at least six different animals. In general, the staining was very similar in animals within each group, and at least in the non-decalcified young femurs, the immunostaining obtained for NGF, TrkA, and p75 was comparable to that obtained for CGRP, TH, and CD-31 in terms of being robust, highly specific, with very low background staining. Because the only group of bones that provided highly robust staining of NGF, TrkA, and p75 were the femurs that were not decalcified, the expression patterns of NGF, TrkA, and p75, which are described below and are presented in Figures 1 to 3 and Table 1 , were all obtained from the non-decalcified young mouse femur.
In the young mouse femur, there was robust and consistent NGF staining of a population of cuboidal shaped, non-CD-31 cells at the subchondral bone/articular cartilage interface. These cells are present in stacked grouping and robustly express NGF immunoreactivity (Figure 1(B) and (C)) and these cells may be mesenchymal progenitor cells or undifferentiated chondrocytes. In the bone marrow and periosteum, robust NGFþ immunoreactivity was observed in association with blood vessels (Figure 2 (A) and (B)). When this staining was first observed, the assumption was that all or at least a significant majority of this staining was present in CD-31þ endothelial cells. However, upon close examination (as can be seen when comparing Figure 3 (A) with (B)) while some of the NGFþ immunoreactivity may co-localize with CD-31þ endothelial cells (arrows), the great majority of NGFþ staining does not co-localize with CD-31þ cells, as these cells have the morphology of pericytes. One other cell type that was frequently found to express NGF in the bone marrow was NGFþ cells (which were not CD-31þ) which appear as single cells or small groups of single cells (arrowheads in Figure 3(A) and (D) ). Although these cells were usually found within 100 mm of NGFþ blood vessels, they do not appear to have any direct connection with the NGFþ blood vessel nor do they have the morphology of NGFþ blood vessels associated cells which are found in both the periosteum and bone marrow (Figure 3(A) and (D) and Table 1 ).
The expression of TrkA in bone
The expression of TrkA in bone appears to be restricted to nerve fibers which appear to have the morphology of either sensory (CGRPþ) or sympathetic (THþ) nerve fibers (Figure 3(C) to (E)). In general, TrkAþ nerve fibers in the bone marrow and periosteum are nearly always found in close association with NGFþ blood vessels (Figure 3(B) ). It should be noted that TrkAþ nerve fibers were not found near the NGFþ cells located near the subchondral bone/articular cartilage interface nor were any TrkAþ cells found in the articular cartilage ( Table 1 ).
The expression of p75 in bone and articular cartilage
The expression of p75 in bone is, with one exception, very similar to the expression of TrkA in bone. In both the bone marrow and periosteum, p75þ (which in the mesenchymal progenitor cell literature is also known as CD271) is present in nerve fibers which have the morphology of sensory (CGRPþ) and sympathetic (THþ) nerve fibers (Figure 3(C) to (E)) and like TrkAþ nerve fibers, p75þ immunoreactive nerve fibers were nearly always closely associated with NGFþ blood vessels. However, unlike TrkA, robust p75 expression was also observed in a subset of cells located in the deep and middle zones of the articular cartilage of the knee joint. The p75þ cells which are located in the middle zone of the articular cartilage (Figures 1(B) and (E)) clearly have the circular, isolated cell morphology characteristics of chondrocytes, whereas the p75þ cells in the deep zone of the articular cartilage have a much more flattened and less differentiated appearance (Figure 1(B) and (D) and Table 1 ).
The effect of decalcification on the immunohistochemical detection of NGF, TrkA, p75, CGRP, TH, and CD-31 in bone
To assess whether decalcification of bone affected our ability to immunohistochemically detect NGF, TrkA, and p75, we examined both non-decalcified vs. decalcified young bones (Figure 4) . In all cases, immunostaining of NGF, TrkA, and p75 was reduced in the decalcified young bones when compared to the non-decalcified young bones. For example, in the young non-decalcified femur, robust NGF immunoreactivity was easily observed in blood vessels, an unidentified group of cells located at the subchondral bone/articular cartilage interface, and a few isolated, single cells in the bone marrow. However, in the decalcified young bone, NGFþ staining was at the limits of being detectable (Figure 4 (G) vs. (H)). Similarly, the robust expression of TrkA and p75 that was observed in nerve fibers (Figure 4(C) and (E), respectively) significantly declined in decalcified bones (Figures 4(D) and (F), respectively) . Notable, decalcification of bone did not affect all antigens equally. Thus, CGRP (Figure 4(A) and (B) ), TH, and CD31 (which were run as positive controls in attempting to localize NGF, p75 and TrkA in adult and aging bones) exhibited 
B). The triangles (1-3) outline the clusters of DAPIþ nuclei to show that what is being shown in (A) is in exact register with (B). Note that there is at best only a partial co-localization (arrows) of NGFþ cells (A) and CD-31þ endothelial cells (B)
. These data suggest that another non-CD-31þ endothelial cells such as pericytes may be the primary NGFþ blood vessel-associated cells in bone. Similar NGFþ blood vessel-associated cells were observed throughout the marrow and periosteum but was not observed in cortical bone as the Haversian canals that vascularize cortical bone had yet to form in these young mice. These confocal images are taken from one 60 mm section where the total z-stack ¼ 60 mm. Line bar ¼ 30 mm. similar robust staining in the non-decalcified young bone and the decalcified young, adult, and aging bone ( Table 2) .
It should be noted that while the immunostaining in the present study is quite robust with low background, it is still subject to all of the limitations of the method. Thus, while antibody specificity is important, it is very difficult to prove in tissue sections. Similarly, while it is clear that the decalcification procedure introduces difficulties, what is not clear is whether the decalcification process induces actual loss of antigen from the tissue or simply the modification of an antigen that is still present, but no longer recognized by the antibody. While we believe it is the latter, we have also tried several forms of antigen retrieval (heating, microwave, etc.; data not shown) in the decalcified young, adult, and aging skeleton and no antigen retrieval protocol has yet to provide the robust staining for NGF, TrkA, or p75 which we were able to detect in the young, non-decalcified bones.
Discussion

Discovery of NGF and its involvement in pain
NGF was initially discovered in the 1950s as a tumor tissue-produced soluble factor that promotes the growth and differentiation of sensory and sympathetic ganglia. 36 NGF was the first growth factor to be identified and its discovery represented a landmark achievement in developmental neurobiology. 37 The illumination of NGF's critical role in neuronal development eventually led to the creation of the ''neurotrophic factor hypothesis'' and the classical neurotrophic model in which NGF is synthesized and released by target tissues during embryonic development, promoting the growth, differentiation, and survival of neurons in a dose-dependent manner. 38 By the postnatal period, TrkA expression and NGF sensitivity decline, and the role of NGF-TrkA signaling shifts from promoting neuron growth and survival to regulating the sensitivity of the peripheral nervous system to noxious stimuli. 39 A role for NGF has been demonstrated in both acute, transient nociceptive responses, as well as in long-term, chronic pain. As early as 1977, a report that NGF exerts effects on mast cells suggested that the physiologic effects of NGF were not limited to neuronal development and maturation. 12 Currently, the NGF-TrkA axis is thought to play a pivotal role in the early, intermediate, and long-term generation and maintenance of several types of acute and chronic pain. 40 Thus, NGF concentrations are increased in chronic pain conditions such as interstitial cystitis, prostatitis, arthritis, pancreatitis, chronic headaches, cancer pain, diabetic neuropathy, and noncancer pain, suggesting that NGF-mediated signaling is an ongoing and active process in chronic nociceptive and neuropathic pain states. 12, [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] Given the evidence that NGF plays an important role in driving skeletal pain, one important data set that we still do not have is what Figure 4 . The effect of decalcification on CGRP, NGF, TrkA, and p75 immunostaining in the femur of the young mouse. These confocal images were taken from young bones that had been fixed and then placed for 14 days in either PBS solution (pH ¼ 7.4, 4 C) (A, C, E, G) or a decalcification solution consisting of PBS þ EDTA (pH ¼ 7.4, 4 C) (B, D, F, H). After 14 days, both the decalcified and non-decalcified femurs were placed in a 30% sucrose solution for two days, frozen sections cut, and the sections then immunostained for CGRP, TrkA, p75, or NGF. Note that robust immunohistochemical staining is observed for CGRP, TrkA, p75, and NGF in bones that were not decalcified (A, C, E, G). In contrast, in bones that had been decalcified, CGRP showed no significant loss of signal following decalcification (B), whereas TrkA (D), p75 (F), and NGF (H) all showed significant loss of immunohistochemical signal. All images presented here were obtained in the bone marrow. z-stack ¼ 60 mm, line bar ¼ 30 mm. ote. Cells that expressed robust NGF immunoreactivity were observed in CD-31À and CD31þ blood vessels, non-CD-31þ cells in subchondral bone and single or small clusters of non-blood vessel-associated cells in the bone marrow. Both TrkA and p75 were abundantly expressed by nerve fibers innervating NGFþ blood vessels in the marrow and periosteum. Robust expression of p75, but not TrkA, was also observed in cells in the deep and middle zone of the articular cartilage. NGF: nerve growth factor; TrkA: tropomyosin receptor kinase A.
specific sets of cells in the intact bone express NGF, TrkA, or p75. 4, 32, 33, 52 Decalcification of bone and the ability to immunohistochemically detect NGF, TrkA, and p75
Previous studies have suggested that the process of bone decalcification can significantly affect the antigenicity of peptides and proteins and the ability to detect the cellular localization of these antigens using immunohistochemistry. 53, 54 Relatively few studies attempted to simultaneously localize NGF, TrkA, and p75 in skeletal tissues and assess the impact of decalcification on the ability to detect these proteins. 12, 30 In the present study, we found robust NGF immunoreactivity in CD-31À and CD-31þ blood vessel-associated cells, CD-31À cells at the interface of subchondral bone and articular cartilage, and single NGFþ cells in bone marrow in non-decalcified bone tissue. In contrast, in young, adult, or aging bones which had been decalcified, robust NGF immunoreactivity became difficult to detect. Similarly, the robust expression of TrkA and p75 in nerve fibers and the p75 expression in chondrocytes observed in the non-decalcified young bone declined significantly in the decalcified young, adult, or aging bone. These results suggest that when exploring antigen expression in skeletal tissues, using a non-decalcified bone as a positive control may provide significant insight into whether the decalcification process is negatively affecting the ability to detect the antigen of interest.
Expression of NGF in normal young bone and articular cartilage
In the present report, the great majority of cells that express NGF in the young bone marrow and periosteum appear to be CD-31þ endothelial cells and CD-31À blood vessel-associated cells. These observations support previous studies showing that endothelial cells and pericytes in the rat heart can express NGF. 55 Previous studies have also shown that depending on the vascular bed, endothelial cells can either be NGFþ or NGFÀ and a similar heterogeneity in NGF expression is also apparent for myocytes. 55 What is clear in the present report is that not all CD-31þ endothelial cells in bone express NGF and that most NGFþ cells in bone do not express CD-31. These data suggest that non-CD31þ blood vessel-associated cells, including pericytes 56 are probably the major cells in the blood vessel that are expressing NGF, rather than the endothelial cell. What is also clear is that in vascular beds in the periosteum and bone marrow, where there are NGFþ cells, there is usually also a significant number of TrkAþ, p75þ, CGRPþ sensory nerve fibers, and THþ post-ganglionic sympathetic nerve fibers that are intimately associated with the NGFþ blood vessel.
In addition to NGFþ blood vessel-associated cells in the bone marrow and periosteum, there was a small subset of NGFþ cells that were located at the interface of the subchondral bone/articular cartilage. These cells did not have the morphology or organization of blood vessels, they did not express CD-31, nor did they have the very distinctive round morphology of chondrocytes. While these cells may secrete NGF that could bind to p75þ chondrocytes that are in the middle zone of the articular cartilage, it is difficult to understand how a large protein such as NGF could diffuse through the articular cartilage to bind to p75þ chondrocytes. One other possibility is that NGF released from these NGFþ cells could interact with TrkAþ sensory nerve fibers that other authors have suggested undergo sprouting in injured subchondral bone in OA. 57 In the present study, there were few if any TrkAþ or p75þ sensory or sympathetic nerve fibers in the vicinity of these NGFþ cells. However, with the pathological deterioration of an osteoarthritic joint, there are frequently significant changes in subchondral bone [58] [59] [60] and studies have suggested that sprouting of nerve fibers can occur into this newly remodeling subchondral bone. Whether these NGFþ cells, or an entirely new type of NGF expressing cells, play a role in the neuritogenesis in OA remains unclear but these NGFþ cells are clearly at the subchondral bone/articular cartilage interface and could release NGF in response to the increased strain and loading that occurs as the osteoarthritic cartilage losses its elasticity and strength with disease progression.
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Expression of TrkA and p75 in the normal young mouse femur
In the normal skeleton of the young mouse when TrkAþ immunoreactivity is in nerve fibers, these TrkA fibers are also usually in close proximity to NGFþ blood vessels and have either a rather linear morphology which is characteristic of CGRPþ sensory nerve fibers or a corkscrew like morphology which is frequently observed in THþ post-ganglionic sympathetic nerve fibers. [64] [65] [66] One notable observation is that we did not observe any TrkA immunoreactivity in non-neuronal cells in the mouse femur and all the TrkA immunoreactivity that was observed was present in nerve fibers.
Similar to TrkA, p75 immunoreactivity was also observed in many nerve fibers that were intimately associated with NGFþ blood vessels. However, unlike TrkA expression, there was also a consistent and robust labeling of p75 immunoreactive cells in the deep and middle zone of the articular cartilage. These p75þ cells have the morphology and location of chondrocytes as they had a round or spherical morphology. Previous studies in both experimental animals and humans have reported p75 immunoreactive chondrocytes in articular cartilage and these p75þ (also known as CD271) in the present study have a very similar morphology to that reported in human articular cartilage.
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Conclusions and limitations
In the young mouse femur, robust NGF immunoreactivity is found in CD-31À and CD-31þ blood vesselassociated cells, in CD-31À cells at the interface of subchondral bone and articular cartilage and occasionally as single or small clusters of cells in bone marrow. In contrast, the great majority of p75 and TrkA expression in bone is present in nerve fibers with p75 but not TrkA expression also being observed in chondrocytes in the articular cartilage. The present study also suggests that decalcification of a skeletal tissue can have a markedly negative impact on NGF, TrkA, and p75 immunostaining.
The limitations of the present study are that the results were obtained in one bone, obtained from one age, one gender, and one strain of mice. As it has been shown that there is very little, if any, effect of inhibiting NGF on baseline pain sensitivity in the absence of pathology, 4, [12] [13] [14] [15] 17, [20] [21] [22] [23] 25, 36, 70 understanding what cells are NGF positive and where its receptors are expressed in pathological skeletal pain states would greatly extend our understanding. In the present study, the only bones that provided interpretable results in terms of being able to simultaneously provide robust staining of NGF, TrkA, and p75 expression in the bone were the young bones which were not decalcified. These data suggest that inclusion of a positive control such as a young nondecalcified bone will help in interpreting immunohistochemical results when using decalcified tissues. Additionally, developing better techniques that can decalcify human and non-human tissues without eliminating or denaturing the epitope recognized by the antibody will be needed to determine how disease, injury, and aging effects the expression of NGF and its receptors in adult and aging animals of both genders.
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